{"product_id":"vygon-five-forces-analysis","title":"Vygon S.A. Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVygon S.A. operates in a specialized medical devices niche where supplier relationships, regulatory barriers, and customer concentration shape competitive intensity, while innovation and distribution scale mitigate new-entrant and substitute threats.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Vygon S.A.’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Grade Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of Vygon S.A.'s high-tech catheters and IV devices depends on medical-grade polymers and stainless alloys that meet ISO 13485 and USP Class VI standards; certified suppliers number fewer than 10 globally for certain high-purity resins. This supplier concentration gives suppliers pricing power—raw material cost swings accounted for ~12% of Vygon's COGS in 2024, per company filings. Supply disruptions, like the 2021 resin shortage that delayed 18% of European shipments industry-wide, can push lead times past 12 weeks and raise unit costs by 6–10%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrict Regulatory Compliance and Validation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers in medical devices must meet ISO 13485 and EU Medical Device Regulation (MDR 2017\/745); audits and CE technical files typically take 6–18 months and cost €50k–€250k per component to validate. Once a supplier is in Vygon S.A.’s technical file, switching triggers re-validation, regulatory submissions, and clinical\/biocompatibility testing that can exceed €200k and 9–12 months, creating high switching costs. This raises supplier bargaining power, stabilizing prices and reducing Vygon’s leverage in negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy and Manufacturing Input Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, European industrial energy costs averaged about €0.24\/kWh for manufacturers, up ~18% since 2021, and sterilization chemical prices rose ~12% year-on-year; suppliers have passed these increases to medical device firms to protect margins. Vygon S.A.’s dependence on energy-intensive components and third-party sterilization limits its bargaining power, leaving the firm to absorb or pass on higher costs, squeezing gross margins—e.g., a 1% raw-cost rise can cut operating margin by ~0.6 percentage points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Global Chemical Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe global chemical and raw-material sector has concentrated: the top 10 chemical firms held ~60% of medical-grade polymer supply by revenue in 2024, shrinking vendor options for Vygon S.A.\u003c\/p\u003e\n\u003cp\u003eLarge conglomerates serve multiple industries and can reallocate capacity to higher-margin sectors, raising input prices or imposing minimum volumes, which weakens Vygon’s negotiating position.\u003c\/p\u003e\n\u003cp\u003eConsolidation reduces Vygon’s ability to pit suppliers against each other, increasing procurement cost volatility and supplier-led lead-time risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop 10 firms ~60% market share (2024)\u003c\/li\u003e\n\u003cli\u003ePrice premia 5–12% for medical-grade polymers (2023–24)\u003c\/li\u003e\n\u003cli\u003eHigher minimum order quantities, longer lead times\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnological Integration of Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWhen Vygon integrates proprietary sensors or coatings from third-party tech firms, it faces technological lock-in that raises supplier bargaining power; a 2024 MedTech Council report found 38% of device redesigns cost over €500,000 when swapping key components.\u003c\/p\u003e\n\u003cp\u003eDependence on a supplier’s roadmap and pricing can inflate COGS and delay launches—Vygon could see margin pressure if a single supplier hikes prices by 10–15% or limits supply.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e38% of redesigns \u0026gt; €500,000 (MedTech Council, 2024)\u003c\/li\u003e\n\u003cli\u003eSingle-supplier price hike risk: 10–15% impact on margins\u003c\/li\u003e\n\u003cli\u003eComponent swaps often require full device redesign\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration risks: certified vendors \u0026lt;10, raw-costs swing margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: \u003cbr\u003efew certified resin\/alloy vendors (\u0026lt;10 for some grades), top-10 chemical firms ~60% market share (2024), and switching\/regulatory revalidation costs \u0026gt;€200k and 9–12 months. Raw-material cost swings drove ~12% of COGS in 2024; a 1% raw-cost rise cuts operating margin ~0.6pp. Single-supplier price shocks (10–15%) or capacity reallocation raise lead times \u0026gt;12 weeks and squeeze margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertified suppliers (certain resins)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10 global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-10 market share (polymers, 2024)\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw materials share of COGS (2024)\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevalidation cost \u0026amp; time\u003c\/td\u003e\n\u003ctd\u003e€\u0026gt;200k; 9–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead-time risk after disruption\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;12 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-supplier price shock\u003c\/td\u003e\n\u003ctd\u003e10–15% impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Vygon S.A., this Porter's Five Forces overview uncovers key competitive drivers, supplier and buyer power, entry barriers, substitute threats, and disruptive forces shaping the company’s pricing, profitability, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Vygon S.A.—fast insight into supplier, buyer, substitute, entrant, and rivalry pressures to streamline strategic choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominance of Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa large portion of vygon sales flow through group purchasing organizations and hospital chains that bundle demand to push prices down in gpos negotiated roughly device spend europe concentrating pricing risk. these buyers now use advanced benchmarking real-world data analytics set target they can shift volume rivals via exclusive contracts if misses targets pressuring margins forcing volume-for-discount tradeoffs.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Healthcare Budget Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEuropean public health systems, Vygon S.A.’s core market, faced combined deficits exceeding €50 billion in 2024–25, forcing tighter procurement and year-over-year device spending cuts of ~3–5% in countries like France and Italy.\u003c\/p\u003e\n\u003cp\u003eBuyers now favor value-based procurement requiring RCT-level evidence and cost-per-QALY proof; 62% of EU tenders in 2025 demanded health-economic models, raising entry costs for niche devices.\u003c\/p\u003e\n\u003cp\u003ePublic payers’ leverage drives average contract discounts of 15–35% and bundled-service deals, constraining Vygon’s pricing power and pushing margin pressure on specialized product lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Clinical Staff\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cphospital buyers push prices down but anesthesiologists and neonatologists resist brand changes due to familiarity training so clinical staff exert high switching costs that protect vygon pricing. a switch of catheter systems typically requires hours retraining per department protocol revisions can cost hospitals according hospital operations reports. resistance offsets procurement pressure gives modest price stability supporting gross margins in the range reported\u003e\n\u003c\/phospital\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Transparency in Global Tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe digitalization of healthcare procurement has raised price transparency in global tenders, letting buyers compare Vygon S.A.’s IV access device prices across regions and hospital networks in real time.\u003c\/p\u003e\n\u003cp\u003eThis visibility compresses price differentiation: a 2024 IQVIA report showed e-procurement reduced bid price variance by ~18% in EU tenders, so Vygon must justify any premium by proving better clinical outcomes or offering specialized support services.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time price comparison increases buyer leverage\u003c\/li\u003e\n\u003cli\u003e~18% bid variance reduction in EU e-procurement (IQVIA 2024)\u003c\/li\u003e\n\u003cli\u003ePremiums need clinical outcome data or service bundles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Integrated Solutions and Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern hospitals now buy integrated clinical solutions—devices plus training and tech support—reducing standalone hardware demand and raising service-level expectations.\u003c\/p\u003e\n\u003cp\u003eCustomers pressing for bundled SLAs shift revenue to lower-margin services, cutting Vygon S.A.’s hardware ASP (average selling price) and squeezing gross margin; medtech surveys in 2024 show 62% of buyers prefer bundled solutions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of buyers prefer bundles (2024)\u003c\/li\u003e\n\u003cli\u003eBundling lowers hardware ASP, pressuring margins\u003c\/li\u003e\n\u003cli\u003eSLA demands increase recurring-service costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGPOs drive deep discounts; e‑procurement, bundles and training shield pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers hold high leverage: GPOs\/tenders set ~45–55% of device spend (2025) and drive 15–35% contract discounts; e-procurement cut bid variance ~18% (IQVIA 2024). Public payer cuts (~€50bn deficits 2024–25) forced −3–5% device spend. Clinical staff switching costs (8–16 training hrs; €20k–€60k) give Vygon modest price protection; 62% of buyers prefer bundled SLAs (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO share\u003c\/td\u003e\n\u003ctd\u003e45–55% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscounts\u003c\/td\u003e\n\u003ctd\u003e15–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBid variance drop\u003c\/td\u003e\n\u003ctd\u003e~18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuyer preference bundles\u003c\/td\u003e\n\u003ctd\u003e62% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eVygon S.A. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Vygon S.A. Porter's Five Forces analysis you'll receive—fully formatted, comprehensive, and ready for immediate download after purchase.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or samples: the content you see here is the final deliverable, covering competitive rivalry, supplier and buyer power, threat of entry, and threat of substitutes.\u003c\/p\u003e\n\u003cp\u003eOnce you complete your purchase, you’ll get instant access to this same professionally written document for use in decision-making or reporting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747464163705,"sku":"vygon-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/vygon-five-forces-analysis.png?v=1772198814","url":"https:\/\/growthsharematrix.com\/products\/vygon-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}